- Home
- GLTO vs NNVC Comparison
GLTO vs NNVC Comparison
Compare GLTO & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLTO
- NNVC
- Stock Information
- Founded
- GLTO 2011
- NNVC 2005
- Country
- GLTO Denmark
- NNVC United States
- Employees
- GLTO N/A
- NNVC N/A
- Industry
- GLTO Biotechnology: Pharmaceutical Preparations
- NNVC Biotechnology: Pharmaceutical Preparations
- Sector
- GLTO Health Care
- NNVC Health Care
- Exchange
- GLTO Nasdaq
- NNVC Nasdaq
- Market Cap
- GLTO 23.7M
- NNVC 23.1M
- IPO Year
- GLTO 2020
- NNVC N/A
- Fundamental
- Price
- GLTO $5.72
- NNVC $1.91
- Analyst Decision
- GLTO
- NNVC
- Analyst Count
- GLTO 0
- NNVC 0
- Target Price
- GLTO N/A
- NNVC N/A
- AVG Volume (30 Days)
- GLTO 767.1K
- NNVC 398.7K
- Earning Date
- GLTO 11-04-2025
- NNVC 10-15-2025
- Dividend Yield
- GLTO N/A
- NNVC N/A
- EPS Growth
- GLTO N/A
- NNVC N/A
- EPS
- GLTO N/A
- NNVC N/A
- Revenue
- GLTO N/A
- NNVC N/A
- Revenue This Year
- GLTO N/A
- NNVC N/A
- Revenue Next Year
- GLTO N/A
- NNVC $133.33
- P/E Ratio
- GLTO N/A
- NNVC N/A
- Revenue Growth
- GLTO N/A
- NNVC N/A
- 52 Week Low
- GLTO $2.01
- NNVC $0.94
- 52 Week High
- GLTO $31.70
- NNVC $2.23
- Technical
- Relative Strength Index (RSI)
- GLTO 42.06
- NNVC 62.45
- Support Level
- GLTO $7.02
- NNVC $1.51
- Resistance Level
- GLTO $7.64
- NNVC $2.23
- Average True Range (ATR)
- GLTO 0.58
- NNVC 0.19
- MACD
- GLTO -0.55
- NNVC 0.04
- Stochastic Oscillator
- GLTO 0.25
- NNVC 61.45
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
About NNVC NanoViricides Inc.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.